Drug intelligence / Profile preview

Figatil

Development stage: Unknown
Lead developer: Laboratório Catarinense
Modality: Small Molecules
Administration: Oral

Overview

Figatil is a traditional phytotherapeutic medicine developed and marketed by Laboratório Catarinense (Catarinense Pharma) in Brazil. It is a combination product containing hydroethanolic dry extracts from artichoke (*Cynara scolymus* L.) and boldo (*Peumus boldus* Molina) leaves. Figatil functions as a choleretic and cholagogue agent, meaning it stimulates bile production in the liver and promotes its flow to the intestine, thereby facilitating digestion. It is primarily indicated for the symptomatic treatment of digestive complaints and gastrointestinal spastic disorders. The product is available in multiple oral formulations, including coated tablets (dragées), oral solution concentrate, and single-dose vials (flaconetes).

Brand names: Figatil
Other names: Cynara scolymus + Peumus boldus

Beyond the preview

Go deeper on Figatil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Figatil.

Explore the full profile